These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 15630675)

  • 1. Monitoring the new antithrombotic drugs.
    Walenga JM; Hoppensteadt DA
    Semin Thromb Hemost; 2004 Dec; 30(6):683-95. PubMed ID: 15630675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standardization of coagulation tests.
    Opartkiattikul N
    Southeast Asian J Trop Med Public Health; 1999; 30 Suppl 3():79-85. PubMed ID: 10926265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
    Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
    Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A primate model (Macaca mulatta) to study the pharmacokinetics of heparin and its fractions.
    Fareed J; Kumar A; Rock A; Walenga JM; Davis P
    Semin Thromb Hemost; 1985 Apr; 11(2):138-54. PubMed ID: 4035364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample.
    Mattsson C; Menschiek-Lundin A; Wåhlander K; Lindahl TL
    Thromb Haemost; 2001 Aug; 86(2):611-5. PubMed ID: 11522011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
    Barrett YC; Wang Z; Frost C; Shenker A
    Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulation monitoring part 1: warfarin and parenteral direct thrombin inhibitors.
    Spinler SA; Nutescu EA; Smythe MA; Wittkowsky AK
    Ann Pharmacother; 2005 Jun; 39(6):1049-55. PubMed ID: 15855245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Monitoring blood coagulation].
    Pabinger-Fasching I
    Wien Med Wochenschr; 1999; 149(2-4):70-1. PubMed ID: 10378328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay.
    Kitchen S; Theaker J; Preston FE
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):137-44. PubMed ID: 10759006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rivaroxaban: mode of action].
    Drouet L
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S9-15. PubMed ID: 19185786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R; Jacobs C
    Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between CoaguChek S- and Owren-type prothrombin time assay for monitoring anticoagulant therapy.
    Jonsson M; Hillarp A; Svensson P
    Thromb Res; 2004; 114(2):83-9. PubMed ID: 15306149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heptest-STAT, a new assay for monitoring of low-molecular-weight heparins, is not influenced by pregnancy-related changes of blood plasma.
    Dempfle CE; Zharkowa U; Elmas E; Ahmad-Nejad P; Neumaier M; Borggrefe M
    Thromb Haemost; 2009 Nov; 102(5):1001-6. PubMed ID: 19888540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
    Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
    Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current trends in antithrombotic drug and device development.
    Fareed J
    Semin Thromb Hemost; 1996; 22 Suppl 1():3-8. PubMed ID: 8807721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Q analyzer, a new cap-piercing fully automated coagulometer with clotting, chromogenic, and immunoturbidometric capability.
    Kitchen S; Woolley A
    Blood Coagul Fibrinolysis; 2013 Jan; 24(1):28-34. PubMed ID: 23249565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methods for the monitoring of direct thrombin inhibitors.
    Hafner G; Roser M; Nauck M
    Semin Thromb Hemost; 2002 Oct; 28(5):425-30. PubMed ID: 12420237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between prothrombin activation fragment (F1.2), cerebral ischemia (S-100beta) and international normalized ratio (INR) in patients with ventricular assisted devices.
    Joshi A; Magder LS; Kon Z; Kallam S; Kwon M; Sangrampurkar R; Pierson R; Poston R
    Interact Cardiovasc Thorac Surg; 2007 Jun; 6(3):323-7. PubMed ID: 17669856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.